{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:22:06Z","timestamp":1792736526195,"version":"4.5.0"},"reference-count":233,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:sec><jats:title>SUMMARY<\/jats:title><jats:p>The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. Cidofovir (Vistide) has been officially approved for the treatment of CMV retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) has been approved for the treatment of HIV infections (i.e., AIDS), and adefovir dipivoxil (Hepsera) has been approved for the treatment of chronic hepatitis B. Nephrotoxicity is the dose-limiting side effect for cidofovir (Vistide) when used intravenously (5 mg\/kg); no toxic side effects have been described for adefovir dipivoxil and tenofovir disoproxil fumarate, at the approved doses (Hepsera at 10 mg orally daily and Viread at 300 mg orally daily).<\/jats:p><\/jats:sec>","DOI":"10.1128\/cmr.16.4.569-596.2003","type":"journal-article","created":{"date-parts":[[2003,10,13]],"date-time":"2003-10-13T18:27:41Z","timestamp":1066069661000},"page":"569-596","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":319,"title":["Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections"],"prefix":"10.1128","volume":"16","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205006"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.3.678"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.83.10.1153"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3727\/096504001108747855"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-81-3-639"},{"key":"e_1_3_2_7_2","first-page":"523","volume":"10","year":"1998","unstructured":"Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. De Clercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res.10:523-531.","journal-title":"Oncol. Res."},{"key":"e_1_3_2_8_2","first-page":"533","volume":"10","year":"1998","unstructured":"Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. De Clercq. 1998. Inhibitory effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic-nude mice. Oncol. Res.10:533-539.","journal-title":"Oncol. Res."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.587"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-19119"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800610"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.17408300"},{"key":"e_1_3_2_13_2","first-page":"1558","volume":"27","year":"1998","unstructured":"Badiaga, S., P. Parola, C. Zandotti, and P. Brouqui. 1998. Successful treatment of Kaposi's sarcoma with a combination of antiviral drug therapy and chemotherapy: two case reports. Clin. Infect. Dis.27:1558.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1999.89"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/15257779508010709"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)70781-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/514057"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/341491"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2381-2386.2002"},{"key":"e_1_3_2_20_2","first-page":"574","volume":"33","year":"2002","unstructured":"Bendele, R. A., and F. C. Richardson. 2002. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum. Pathol.33:574.","journal-title":"Hum. Pathol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05840-8"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/313593"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200204000-00019"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200202270-00033"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00118-5"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1610-1613.2002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.3.716-723.2002"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/517060"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199705010-00014"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702591"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/319984"},{"key":"e_1_3_2_32_2","first-page":"446","volume":"87","year":"2002","unstructured":"Bosi, A., B. Bartolozzi, A. M. Vannucchi, A. Orsi, S. Guidi, and P. Rossi Ferrini. 2002. Polymerase chain reaction-based \u201cpre-emptive\u201d therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica87:446-447.","journal-title":"Haematologica"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050440"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/315190"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00220-0"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1067\/moe.2000.110413"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00184.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.8.932"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/314052"},{"key":"e_1_3_2_40_2","first-page":"91","volume":"5","year":"1997","unstructured":"Cherrington, J. M. 1997. Human cytomegalovirus: resistance profile of cidofovir. Int. Antiviral News5:91-92.","journal-title":"Int. Antiviral News"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.9.2212"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.4.987"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1067\/mhn.2002.125604"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2495-2501.2001"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00124-8"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1201-1209.2001"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.3.570"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00210-8"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9299"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1135\/cccc19920661"},{"key":"e_1_3_2_51_2","first-page":"1502","volume":"50","year":"1996","unstructured":"Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol.50:1502-1510.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800302"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.7.3.223.3999"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90670-R"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1086\/318447"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2740-2745.2001"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936020-00004"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.687"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.4.1210"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01782-1"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.100534"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90276-B"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1980030205"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1980050305"},{"key":"e_1_3_2_65_2","first-page":"19","volume":"58","year":"1996","unstructured":"De Clercq E. 1996. Therapeutic potential of cidofovir (HPMPC, Vistide\u2122) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh. K. Acad. Geneeskd. Belg.58:19-49.","journal-title":"Verh. K. Acad. Geneeskd. Belg."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(97)00031-9"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.2.382-397.2001"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00008-6"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(02)02091-6"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.701"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.336"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1086\/514150"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2380"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1586-1588.2002"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.425-433.2002"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.4.891"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537256"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001280-00006"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1086\/515153"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)00962-0"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04101.x"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00080-2"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-100002496"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.7.1.1"},{"key":"e_1_3_2_85_2","first-page":"1136","volume":"141","year":"1999","unstructured":"Fife, K., J. Gill, D. Bourboulia, B. Gazzard, M. Nelson, and M. Bower. 1999. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Br. J. Dermatol.141:1136-1153.","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109070-00013"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)00985-X"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/13550280152537274"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1084"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1999.00182.x"},{"key":"e_1_3_2_91_2","first-page":"44","volume":"3","year":"2001","unstructured":"Gonz\u00e1lez-Fraile, M. I., C. Canizo, D. Caballero, R. Hern\u00e1ndez, L. V\u00e1zquez, C. L\u00f3pez, A. Izarra, J. L. Arroyo, A. de la Loma, M. J. Otero, and J. F. San Miguel. 2001. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transplant. Infect. Dis.3:44-46.","journal-title":"Transplant. Infect. Dis."},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-199609000-00018"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021812"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1086\/318120"},{"key":"e_1_3_2_95_2","first-page":"1233","volume":"26","year":"1998","unstructured":"Hammoud, Z., D. M. Parenti, and G. L. Simon. 1998. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin. Infect. Dis.26:1233.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_96_2","first-page":"491","volume":"24","year":"2001","unstructured":"H\u00e4nel, M., F. Fiedler, and C. Thorns. 2001. Anti-CD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie24:491-494.","journal-title":"Onkologie"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1067-1072.2002"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.76.2.143"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.10.1487"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)00992-2"},{"key":"e_1_3_2_101_2","first-page":"197","volume":"41","year":"1992","unstructured":"Ho, H.-T., K. L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine. Mol. Pharmacol.41:197-202.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2001.v7.pm11529489"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1041-1046.2000"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155500750012333"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1086\/515167"},{"key":"e_1_3_2_106_2","first-page":"40848","volume":"276","year":"2001","unstructured":"Johnson, A. A., A. S. Ray, J. Hanes, Z. Suo, J. M. Colacino, K. S. Anderson, and K. A. Johnson. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem.276:40848-40857.","journal-title":"J. Biol. Chem."},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00223-6"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.24.2305"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.7.925"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119380"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.991-995.2002"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1086\/515534"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30985-2"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71233-4"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1036"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04747.x"},{"key":"e_1_3_2_117_2","first-page":"1005","volume":"49","year":"1996","unstructured":"Kramata, P., I. Votruba, B. Otov\u00e1, and A. Hol\u00fd. 1996. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases \u03b1, \u03bb and \u03b5. Mol. Pharmacol.49:1005-1011.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/44.2.97"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199804010-00008"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-4-199702150-00001"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1086\/516542"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.4.788"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.3.570"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.9.1169"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702820"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1444-1449.2001"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K"},{"key":"e_1_3_2_128_2","first-page":"2562","volume":"58","year":"1998","unstructured":"Liekens, S., G. Andrei, M. Vandeputte, E. De Clercq, and J. Neyts. 1998. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res.58:2562-2567.","journal-title":"Cancer Res."},{"key":"e_1_3_2_129_2","first-page":"5057","volume":"61","year":"2001","unstructured":"Liekens, S., J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta. 2001. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res.61:5057-5064.","journal-title":"Cancer Res."},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.388"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1086\/517101"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00006"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020681"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200206140-00004"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00003"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200106000-00007"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00026"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890440061010"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199711000-00006"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90110-5"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1086\/314560"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200108150-00005"},{"key":"e_1_3_2_143_2","first-page":"7875","volume":"61","year":"2001","unstructured":"Murono, S., N. Raab-Traub, and J. S. Pagano. 2001. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res.61:7875-7877.","journal-title":"Cancer Res."},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.6.860"},{"key":"e_1_3_2_145_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","volume":"6","year":"2001","unstructured":"Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Ther.6:115-126.","journal-title":"Antiviral Ther."},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-100002340"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2179-2184.2002"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800101"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00130-3"},{"key":"e_1_3_2_150_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2754"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410312"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.170"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967257"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890370112"},{"key":"e_1_3_2_155_2","first-page":"384","volume":"58","year":"1998","unstructured":"Neyts, J., R. Sadler, E. De Clercq, N. Raab-Traub, and J. S. Pagano. 1998. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res.58:384-388.","journal-title":"Cancer Res."},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(90)90271-R"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(91)90057-X"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958030-00010"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200202150-00017"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.20.9771-9775.2000"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922201316912772"},{"key":"e_1_3_2_162_2","first-page":"129","volume":"32","year":"2000","unstructured":"Perrillo, R., E. Schiff, E. Yoshida, A. Statler, K. Hirsch, T. Wright, K. Gutfreund, P. Lamy, and A. Murray. 2000. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology32:129-134.","journal-title":"Hepatology"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199912270-00017"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200104150-00010"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958020-00015"},{"key":"e_1_3_2_166_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.882"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2000.0704"},{"key":"e_1_3_2_168_2","first-page":"1143","volume":"125","year":"1999","unstructured":"Pransky, S. M., A. E. Magit, D. B. Kearns, D. R. Kang, and N. O. Duncan. 1999. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch. Otolaryngol. Head Neck Surg.125:1143-1148.","journal-title":"Head Neck Surg."},{"key":"e_1_3_2_169_2","first-page":"1239","volume":"126","year":"2000","unstructured":"Pransky, S. M., D. F. Brewster, A. E. Magit, and D. B. Kearns. 2000. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg.126:1239-1243.","journal-title":"Head Neck Surg."},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(99)00069-4"},{"key":"e_1_3_2_171_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.11.1171"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703123161106"},{"key":"e_1_3_2_173_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03769.x"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)00058-5"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1086\/517222"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00166-8"},{"key":"e_1_3_2_177_2","first-page":"378","volume":"40","year":"1999","unstructured":"Romanowski, E. G., S. P. Bartels, and Y. J. Gordon. 1999. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Investig. Ophthalmol. Visual Sci.40:378-384.","journal-title":"Investig. Ophthalmol. Visual Sci."},{"key":"e_1_3_2_178_2","first-page":"460","volume":"41","year":"2000","unstructured":"Romanowski, E. G., and Y. J. Gordon. 2000. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Investig. Ophthalmol. Visual Sci.41:460-463.","journal-title":"Investig. Ophthalmol. Visual Sci."},{"key":"e_1_3_2_179_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2996"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100720170031"},{"key":"e_1_3_2_181_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200206140-00008"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005260-00029"},{"key":"e_1_3_2_183_2","first-page":"678","volume":"12","year":"1998","unstructured":"Sch\u00fcrmann, D., F. Bergmann, M. P. Grobusch, M. Behnsch, and A. Liekfeld. 1998. Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir. AIDS12:678-679.","journal-title":"AIDS"},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012108719462"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200003010-00002"},{"key":"e_1_3_2_186_2","first-page":"1562","volume":"27","year":"1998","unstructured":"Simonart, T., J.-C. Noel, E. De Clercq, and R. Snoeck. 1998. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin. Infect. Dis.27:1562.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_187_2","first-page":"215","volume":"55","year":"1988","unstructured":"Simonart, T., J.-C. Noel, G. De Dobbeleer, D. Parent, J.-P. Van Vooren, E. De Clercq, and R. Snoeck. 1988. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case. J. Med. Virol.55:215-218.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1837"},{"key":"e_1_3_2_189_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00159-0"},{"key":"e_1_3_2_190_2","first-page":"171","volume":"47","year":"2001","unstructured":"Smee, D. F., K. W. Bailey, M.-H. Wong, and R. W. Sidwell. 2001. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res.47:171-177.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_191_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020101200105"},{"key":"e_1_3_2_192_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800612"},{"key":"e_1_3_2_193_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1329-1335.2002"},{"key":"e_1_3_2_194_2","doi-asserted-by":"publisher","DOI":"10.1086\/514041"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0609"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309233291317"},{"key":"e_1_3_2_197_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(200002)60:2<205::AID-JMV16>3.0.CO;2-8"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1086\/322593"},{"key":"e_1_3_2_199_2","first-page":"943","volume":"333","year":"1995","unstructured":"Snoeck, R., M. Van Ranst, G. Andrei, E. De Clercq, S. De Wit, M. Poncin, and N. Clumeck. 1995. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med.333:943-944.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1839"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<219::AID-JMV13>3.0.CO;2-C"},{"key":"e_1_3_2_202_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.19.2382"},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.6.1484"},{"key":"e_1_3_2_204_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2213"},{"key":"e_1_3_2_205_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800102"},{"key":"e_1_3_2_207_2","doi-asserted-by":"publisher","DOI":"10.1086\/314496"},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200203010-00001"},{"key":"e_1_3_2_209_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199904010-00001"},{"key":"e_1_3_2_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00019-0"},{"key":"e_1_3_2_211_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-4-199702150-00002"},{"key":"e_1_3_2_212_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007280-00013"},{"key":"e_1_3_2_213_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00840-6"},{"key":"e_1_3_2_214_2","first-page":"983","volume":"136","year":"2000","unstructured":"Toro, J. R., L. V. Wood, N. K. Patel, and M. L. Turner. 2000. Topical cidofovir. A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus type 1. Arch. Dermatol.136:983-985.","journal-title":"Arch. Dermatol."},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5239.1197"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.707"},{"key":"e_1_3_2_217_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1034\/j.1600-0684.2000.290318.x","volume":"29","year":"2000","unstructured":"Tsai, C.-C., P. Emau, J. C. Sun, T. W. Beck, C.-A. Tran, K. E. Follis, N. Bischofberger, and W. R. Morton. 2000. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection. J. Med. Primatol.29:248-258.","journal-title":"J. Med. Primatol."},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890450221"},{"key":"e_1_3_2_219_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2586"},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.1086\/322781"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.4.1767-1774.2000"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.4.2947-2955.1999"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.1086\/318497"},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200301150-00020"},{"key":"e_1_3_2_225_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.3.436"},{"key":"e_1_3_2_226_2","first-page":"96","volume":"38","year":"2003","unstructured":"Westland, C. E., H. Yang, W. E. Delaney IV, C. S. Gibbs, M. D. Miller, M. Wulfsohn, J. Fry, C. L. Brosgart, and S. Xiong. 2003. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology38:96-103.","journal-title":"Hepatology"},{"key":"e_1_3_2_227_2","doi-asserted-by":"publisher","DOI":"10.1177\/014556130007900407"},{"key":"e_1_3_2_228_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.594"},{"key":"e_1_3_2_229_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.8.1596"},{"key":"e_1_3_2_230_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34740"},{"key":"e_1_3_2_231_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550150040032"},{"key":"e_1_3_2_232_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70046-5"},{"key":"e_1_3_2_233_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1525-1470.1999.016005406.7.x","volume":"16","year":"1999","unstructured":"Zabawski, E. J., Jr., and C. J. Cockerell. 1999. Topical cidofovir for molluscum contagiosum in children. Pediatr. Dermatol.16:414-415.","journal-title":"Pediatr. Dermatol."},{"key":"e_1_3_2_234_2","first-page":"190","volume":"6","year":"2001","unstructured":"Zimmermann, T., K. Stingele, M. Hartmann, J. Haas, R. von Einsiedel, and B. Wildemann. 2001. Succesful treatment of AIDS related PML with HAART and cidofovir. Eur. J. Med. Res.6:190-192.","journal-title":"Eur. J. Med. Res."}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.16.4.569-596.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.16.4.569-596.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:11:24Z","timestamp":1704931884000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.16.4.569-596.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":233,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1128\/CMR.16.4.569-596.2003"],"URL":"https:\/\/doi.org\/10.1128\/cmr.16.4.569-596.2003","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"2003-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}